FDA rejects J&J premature ejaculation drug

Share this article:
The FDA has rejected Johnson & Johnson's application for its experimental drug to treat premature ejaculation, the company said yesterday.
J&J's Alza unit said it plans to address the questions raised by the FDA in its not approvable letter and continue developing the drug.
Alza did not provide further details on why the FDA did not approve the drug.
In a statement, the J&J unit said it "continues to believe that dapoxetine provides important benefits for men who suffer from (premature ejaculation)."
Currently, there are no FDA approved drugs on the market to treat premature ejaculation, a distinct medical condition recognized by the American Urological Association, among other groups.
Share this article:

Email Newsletters

More in Business Briefs

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.

IRS struggles with device tax

A Treasury report says the IRS is having trouble identifying who owes it money.

White House proposes Hobby Lobby alternative

A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.